Over the past 90 days, Avalyn Pharma Inc. recorded four insider buy transactions totaling approximately $25 million. Three distinct insiders, including SR One Capital Management, LLC and Novo Holdings A/S, executed these purchases on May 1, 2026. No insider selling activity was reported during this period, despite the company's recent stock price decline and negative earnings report.